Avidity Biosciences to Participate in Upcoming Investor Conference

Rhea-AI Summary

Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation in the Cowen 43rd Annual Healthcare Conference on March 7 at 8:10 a.m. PT / 11:10 a.m. ET. A live webcast will be available on the 'Events and Presentations' page of Avidity's website, providing up-to-date details and an archived replay. Avidity is focused on developing a new class of RNA therapeutics, known as Antibody Oligonucleotide Conjugates (AOCs™), and currently has three programs in clinical development targeting various muscular dystrophies. The company aims to address previously untreatable diseases through its innovative therapies.

SAN DIEGO, March 1, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following conference:

• Cowen 43^rd Annual Healthcare Conference on March 7 at 8:10 a.m. PT/11:10 a.m. ET

A live webcast of the event, up-to-date event details and an archived replay of the webcast, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.

Investor Contact:
Kathleen Gallagher
(858) 401-7900 x550
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-301756172.html

SOURCE Avidity Biosciences, Inc.

FAQ

What conference will Avidity Biosciences participate in on March 7, 2023?

Avidity Biosciences will participate in the Cowen 43rd Annual Healthcare Conference on March 7, 2023.

What time does Avidity's presentation start at the Cowen Conference?

Avidity's presentation at the Cowen Conference will start at 8:10 a.m. PT / 11:10 a.m. ET.

Where can I watch the Avidity Biosciences conference presentation?

You can watch Avidity Biosciences' conference presentation via a live webcast on their website's 'Events and Presentations' page.

What is the main focus of Avidity Biosciences?

Avidity Biosciences focuses on delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).

What diseases are Avidity Biosciences' AOCs targeting?

Avidity Biosciences' AOCs target various muscular dystrophies, including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.